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Abstract 
Direct-acting antivirals, asunaprevir (ASV), daclatasvir (DCV), and beclabuvir 
(BCV) are known to be mainly metabolized by CYP3A enzymes; however, the 
differences in the detailed metabolic activities of CYP3A4 and CYP3A5 on these drugs 
are not well clarified. The aim of the present study was to elucidate the relative 
contributions of CYP3A4 and CYP3A5 to the metabolism of ASV, DCV, and BCV as 
well as the effect of CYP3A5*3 genetic variant in vitro. The amount of each drug and 
their major metabolites were determined using LC-MS/MS. Recombinant CYP3As and 
CYP3A5*3-genotyped human liver microsomes (CYP3A5 expressers or non-expressers) 
were used for the determination of their metabolic activities. The contribution of 
CYP3A5 to ASV metabolism was considerable compared to that of CYP3A4. 
Consistently, ASV metabolic activity in CYP3A5 expressers was higher than those in 
CYP3A5 non-expresser. Moreover, CYP3A5 expression level was significantly 
correlated with ASV metabolism. In contrast, these observations were not found in DCV 
and BCV metabolism. To our knowledge, this is the first study to directly demonstrate 
the effect of CYP3A5*3 genetic variants on the metabolism of ASV. The findings of the 
present study may provide basic information on ASV, DCV, and BCV metabolisms. 
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Introduction 
Hepatitis C is a hepatic disease caused by the hepatitis C virus (HCV) infection. 
There are at least seven different HCV genotypes (GT) (ref. 1). The global distribution 
of the HCV GTs is complex. In general, GT1, 2, 3, and 4 are widely distributed across 
geographic areas and GT 5, 6, and 7 are the most restricted (ref. 1, 2). GT1 is commonly 
observed in many areas including Asia, Europe, South and North America, and 
Australia, while GT2 is more restricted and frequently found in West Africa and 
parts of South America. GT3 is typically dominant in South Asia and GT4 is 
frequently found from central Africa to the Middle East. GT1 is the most prevalent 
HCV GT worldwide at 46%, followed by GT3 (22%), GT2 (13%), and GT4 
(13%) (ref. 2). Interferon (IFN)-based therapy in combination with ribavirin, 
aiming at stimulating patient’s immune system to eliminate HCV virus, was once the 
standard treatment against HCV GT1 infection worldwide. However, the incidence of 
significant adverse effects (AEs) including interstitial pneumonia, depression, suicide 
ideation, and thrombocytopenia caused by IFN was relatively high, and the rate of 
sustained virological responses (SVR), which is defined as undetectable HCV 
RNA expressions in the blood after certain period of treatment duration, was 
unsatisfied. In recent years, several direct-acting antivirals (DAAs) have been 
developed (ref. 3). DAAs have higher SVR 
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rate, weaker AEs, and shorter treatment durations than IFN-based therapy (ref. 4). The 
IFN-based therapy has been therefore replaced by DAAs. 
Asunaprevir (ASV) and daclatasvir (DCV) (Figures 1A and 1B) are the 
first developed DAAs, and they were approved as the first oral DAA combination 
therapy against HCV GT1 globally. These two DAAs have different targeted-sites on 
HCV. ASV and DCV act as a nonstructural protein 3 protease inhibitor and as a 
5A replication complex inhibitor, respectively (ref. 5, 6). ASV/DCV 
combination therapy has significantly contributed to the improved SVR rate in 
HCV GT1 infection (ref. 7). However, it has been known that mutated-HCV 
exhibits resistance to ASV and DCV (ref. 8, 9). Beclabuvir (BCV, Figure 1C) is 
a nonstructural protein 5B replication complex inhibitor (ref. 10). BCV showed 
additive synergistic effects on replicon inhibition to particularly the resistant HCV 
in combination with ASV/DCV (ref. 10–12). SVR rate was further improved 
using a combination tablet composed of ASV/DCV/BCV (ref. 13), although 
the risk of several AEs such as liver injury still remains. 
The cytochrome P450 (CYP) 3A family of enzymes is important in the 
metabolism of numerous clinically used drugs including several DAAs. Four CYP3A 
isoforms have been reported in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43 
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(ref. 14). Because CYP3A7 is a predominant enzyme in fetal liver and CYP3A43 is 
expressed at low levels, CYP3A4 and CYP3A5 are the two major CYP3A enzymes 
responsible for drug metabolism in adult human liver (ref. 14, 15). Recent studies 
have shown that CYP3A4 and CYP3A5 exhibit some differences in substrate 
specificity (ref. 16, 17). For example, the immunosuppressive drug tacrolimus is 
predominantly metabolized by CYP3A5. Therefore, the expression level of 
CYP3A5 affects the metabolic rate of this drug more significantly than the expression 
level of CYP3A4 does (ref. 18–20). A recent paper elucidated the X-ray crystal 
structure of CYP3A5 by using ritonavir (RTV), which is a substrate/strong inhibitor 
for both CYP3A4 and CYP3A5, and compared the structure of CYP3A5 with that of 
CYP3A4 (ref. 21). CYP3A4 and CYP3A5 share 84% of their amino acid 
sequence and the secondary and tertiary structures are very similar; however, the 
architecture of their active sites is different. This may cause the difference in 
substrate specificities between CYP3A4 and CYP3A5. Importantly, all the three 
DAAs; ASV, DCV, and BCV, are considered to be mainly metabolized by CYP3A 
enzymes (ref. 22–24). However, the differences in the detailed metabolic activities of 
these three drugs between CYP3A4 and CYP3A5 are ambiguous. The most 
investigated and common CYP3A genetic variant is CYP3A5*3, which 
contributes to substantial inter-individual variation in the protein expression of CYP3A5 
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(ref. 25). Individual homozygous for CYP3A5*3 allele either do not express or 
expresses faint amount of CYP3A5 protein. Thus, CYP3A5*3 variant may change the 
metabolism of drugs are predominantly metabolized by CYP3A5 or by both CYP3A4 
and CYP3A5. 
There are still a few difficult-to-treat patients even with the use of the 
combination tablet of ASV/DCV/BCV. The AEs, such as alanine aminotransferase 
(ALT) elevation, occur in approximately 50% of patients, and it is strongly 
recommended to monitor the liver function of patients while using the ASV/DCV/BCV 
combination therapy (ref 26). Importantly, there is a need to stop using the tablet of 
ASV/DCV/BCV when severe AEs are observed. However, the detailed mechanism and 
the significant mechanistic factors for the interindividual-variation in the incidence of 
AEs caused by these drugs have not yet been elucidated. If the contributions of 
CYP3A5 to the metabolism of these drugs are significant, it is likely that CYP3A5 
expression defined as information on the CYP3A5*3 variant may affect the blood 
concentration of ASV, DCV, and BCV and the incidence of AEs via changing their 
metabolic ratio. 
In this study, the detailed relative contributions of CYP3A4 and CYP3A5 to 
metabolism of ASV, DCV, and BCV in vitro were elucidated in recombinant CYP3As 
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(rCYP3A). Moreover, the effects of CYP3A5*3 variant on the metabolism to these three 
drugs were examined by using human liver microsome (HLM). To our knowledge, this 
is the first study to suggest directly one of mechanical factors for inter-individual 
variation of ASV, DCV, and BCV metabolisms. 
To Journal of Human Genetics 
Materials and methods 
Materials 
ASV, DCV, BCV, and RTV were purchased from Chem Scene (Monmouth 
Junction, NJ). Unless otherwise indicated, all chemicals and solvents were of the 
highest commercial or LC-MS/MS grade and purchased from Wako (Osaka, Japan). 
rCYP3A4, rCYP3A5 (microsomes from baculovirus-infected insect cells containing 
human cytochrome P450 reductase and human cytochrome b5 with cDNA-expressed 
human CYP3A4 or CYP3A5), and NADPH regenerating solution were purchased from 
Corning Gentest (Woburn, MA). Control microsomes from baculovirus-infected 
insect cells containing human cytochrome P450 reductase and human cytochrome b5 
without cDNA-expressed human CYP3As (Corning Gentest) were used as a 
baseline for all experiments. Thirty-nine frozen human liver tissues obtained from 
Human and Animal Bridging Research Organization (Chiba, Japan) in our previous 
study were used in the present study (Subject distribution by race and ethnicity: 28 
White (72%), 6 Hispanic (15%), 3 African American (8%), and 2 Asian (5%)) (ref. 
27). The present study was approved by the recombinant DNA experiments safety 
committees of both Okayama University (Approval No. 18089) and International 
University of Health and Welfare (Approval No. D18001), and the research 
ethics committees of both Okayama 
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University (Research No. 1711-018) and the International University of Health and 
Welfare (Approval No. 14-Io-131). 
CYP3A5 genotyping, HLM preparation, and determination of CYP3As content in 
HLM 
Genomic DNA isolation, CYP3A5*3 genotyping, HLM preparation, and 
determination of CYP3A4 and CYP3A5 protein contents in each HLM were carried out 
as described previously (ref. 27). Briefly, genomic DNA was isolated from frozen 
human liver tissues using DNAzol® (Invitrogen, Carlsbad, CA) according to 
manufacturer’s instruction, and HLMs were prepared using ultracentrifugation methods. 
The genotyping of CYP3A5*3 from each human liver was carried out using 
PCR-restriction fragment length polymorphism method with DraI (Takara, Shiga, 
Japan) and specific primers (Forward,
5’-CTAACCATAATCTCTTTTAAGAGCTCTTTTGTCTTTAA-3’; Reverse,
5’-ACTTTGATCATTATGTTATGTAATCCATAC-3’). Individual HLMs were used in 
the correlation analysis, and two pooled HLMs were prepared by mixing equal amounts 
and concentrations of 12 HLMs genotyped with CYP3A5*1/*1 or *1/*3 (designated as 
CYP3A5 expressers) and 27 HLMs genotyped with CYP3A5*3/*3 (designated as 
To Journal of Human Genetics 
CYP3A5 non-expressers), respectively. 
Measurement of drug-metabolizing activity in rCYP3As and HLM 
ASV, DCV, and BCV were dissolved and serially diluted with DMSO to the 
desired concentrations. Incubation mixtures (300 µL final volume) containing rCYP3A4, 
rCYP3A5 (50 pmol/mL), or HLMs (1.0 mg/mL), and various concentration of ASV 
(0–100 µM), DCV (0–100 µM), and BCV (0–150 µM) in 0.1 M potassium phosphate 
(pH 7.4) were pre-incubated at 37 °C for 10 min. The reaction was initiated by adding 
NADPH regenerating solution and further incubated at 37 °C before the desired period. 
For inhibition studies, the CYP3As inhibitor ketoconazole (Wako) was added to the 
incubation mixtures before pre-incubation and was then incubated with each compound 
for 60 min. The concentrations of ketoconazole (1 mM) were determined based on 
referred articles (ref. 27, 28). The final concentration of DMSO was set to be less than 
1% in the reaction mixture to minimize its influence on CYP activities. The reaction 
was terminated by the addition of 1 mL cool acetonitrile/methanol (1:1, v/v) containing 
an internal standard (IS) RTV (10 ng/mL), followed by aggressive vortexing, and 
cooling on ice. The mixture was centrifuged at 10,000 x g for 5 min at 4 °C. The aliquot 
of the supernatant was directly injected into a liquid chromatography-tandem mass 
11 
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spectrometry (LC-MS/MS) system. 
LC-MS/MS analysis 
The LC-MS/MS system and mobile phase condition were as described 
previously (ref. 27). The multiple reaction monitoring ion transition was in accordance 
with studies as follows : m/z 748→648 for ASV, 764→664 for M3/M7 (the same m/z) 
from ASV, 734→634 for M6 from ASV, 557→457 for M9 from ASV, 739→565 for 
DCV, 755→581 for M3 from DCV, 660→535 for BCV, 646→553 for M1 from BCV 
(structures are all shown in Figure 1), and 722→296 for RTV (ref 22, 23, 29). Analyst 
software was used for data acquisition, instrument control, and data analysis. The 
amount of all the compounds was normalized by an IS. Due to lack of pure metabolite, 
the peak areas were used to express kinetic parameters for each metabolite formation 
from the parent compound. To calculate this, the peak area for each sample was divided 
by the ratio of IS peak area at 0 min to the IS at each time. 
Kinetic analysis 
Apparent kinetic parameters were determined by the best fitting of one of the 
following models using GraphPad Prism 5 (GraphPad, San Diego, CA): 
12 
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Michaelis-Menten equation (eq. 1), allosteric sigmoidal (eq. 2), or substrate inhibition 
(eq. 3) (ref. 30). Vmax, Km, [S], h, S50, and Ki represent maximum enzyme velocity, the 
Michaelis-Menten constant, substrate concentration, the Hill slope, the substrate 
concentration needed to achieve a half-maximum enzyme velocity, and the dissociation 
constant for substrate binding, respectively. 
v = Vmax [S]/(Km + [S]) (eq. 1) 
v = Vmax [S]
h/(S50 + [S]
h) (eq. 2) 
v = Vmax [S]/(Km + [S](1 + [S]/Ki)) (eq. 3) 
Vmax/Km value was represented as CLint (intrinsic clearance) (ref. 30). When h 
exceeded 1.0, CLmax (apparent maximal clearance) was calculated by the following 
formula (eq. 4) (ref. 30). 
CLmax = v/[S] = (Vmax/S50/h) × (h – 1)
1-1/h  (eq. 4) 
Statistical analysis 
Statistical analyses were performed using SPSS version 23.0 (IBM, Chicago, 
IL). Paired Student’s t test, Mann-Whitney U test, and Pearson’s correlation coefficient 
were used for comparison of two mean groups and for the correlations between two 
variables. P < 0.05 indicated statistical significance. 
13 
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Results 
Detection of ASV, DCV, BCV, and their metabolites 
Based on the previous reports (ref. 22, 23, 29), the detection methods for ASV, 
DCV, and BCV were established with simple modification in the present study. The 
significant peaks of ASV, DCV, and BCV were detected in the established method 
(Supplementary figure 1). The linear regression analysis showed that the calibration 
curve for each compound was well-fitted in the range of 1–600 ng/mL for ASV, 1–800 
ng/mL for DCV, and 0.1–50 ng/mL for BCV (Supplementary figure 2). The intra- and 
inter-day precision and accuracy of the established method were determined by the 
addition of five concentrations of each compound (Supplementary tables 1–3). The 
coefficients of variation value (%CV) precision were less than 5%. The mean accuracies 
calculated as the percentage of the nominal concentration were also less than 5%. 
Optimization was performed to detect ASV, DCV, and BCV metabolites based 
on m/z information reported previously (ref. 22, 23, 29). Significant peaks for M3/M7, 
M6, and M9 from ASV, M3 from DCV, and M1 from BCV were detected 
(Supplementary Figure 1). Significant correlations between the amounts of the parent 
compound and the relative peak areas for each metabolite were observed (Figure 1).  
14 
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Differences in the metabolic activities of ASV, DCV, and BCV between rCYP3A4 
and rCYP3A5 
The differences in metabolite formations from ASV, DCV, and BCV between 
rCYP3A4 and rCYP3A5 respectively were investigated. ASV was metabolized by both 
rCYP3A4 and rCYP3A5 at nearly the same disappearance rate with both enzymes 
(Supplementary figure 3A). ASV was almost completely metabolized by both rCYP3A4 
and rCYP3A5 after 60 min. Regarding ASV metabolites, the allosteric sigmoidal model 
for M3/M7 and M6 and the Michaelis-Menten model for M9 were fitted (Figures 
2A–2C). The detailed kinetic values of each metabolite formation from ASV in 
rCYP3As are summarized in Tables 1A and 2A. The S50 value of M3/M7 formations for 
rCYP3A5 was lower than that for rCYP3A4, while the S50 and Km values of M6 and M9 
formations for rCYP3A5 were higher than those for rCYP3A4. The Vmax value of M6 
formation for rCYP3A5 was higher than that for rCYP3A4, while the Vmax values of 
M3/M7 and M9 formations for rCYP3A5 were lower than those for rCYP3A4. 
Considering CLint and CLmax values for each formation, M3/M7 formations activity 
(CLmax) by rCYP3A5 was higher than that by rCYP3A4, while M6 and M9 formations 
activities (CLmax for M6 and CLint for M9) by rCYP3A5 were almost half of those by 
rCYP3A4. 
15 
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DCV was primarily metabolized by rCYP3A4, with only 20% of DCV 
remaining after 80 min incubation with rCYP3A4 compared to no significant 
disappearance after incubation with rCYP3A5 (Supplementary figure 3B). In contrast, 
BCV was metabolized by both rCYP3A4 and rCYP3A5, although BCV was completely 
metabolized more quickly by rCYP3A4 (60 min) than by rCYP3A5 (80 min) 
(Supplementary figure 3C). Regarding DCV and BCV metabolites, substrate inhibition 
model for M3 from DCV and Michaelis-Menten model for M1 from BCV were fitted 
(Figures 2D and 2E), respectively. The Km and Vmax values of M3 formation from 
DCV for rCYP3A5 were higher and lower than those for rCYP3A4, respectively. The 
Km and Vmax values of M1 formation from BCV for rCYP3A5 were lower than 
those for rCYP3A4. Considering the results on CLint values, both DCV and BCV 
metabolic activities by rCYP3A5 were lower than those by rCYP3A4. In particular, the 
formation activity of M3 from DCV by rCYP3A5 was almost negligible compared to 
that by rCYP3A4. 
Differences in the metabolic activities of ASV, DCV, and BCV between CYP3A5 
expressers and CYP3A5 non-expressers 
The metabolic activities of ASV, DCV, and BCV in CYP3A5 expressers were 
To Journal of Human Genetics 
respectively compared to those in CYP3A5 non-expressers. The results were almost 
consistent with those obtained from rCYP3As described above. Concerning ASV 
metabolism in HLMs, the allosteric sigmoidal model for M3/M7 and M6 and the 
Michaelis-Menten model for M9 were fitted as with those in rCYP3As, respectively 
(Figures 3A–3C). The detailed kinetic values in HLMs are summarized in Tables 1B 
and 2B. The S50 value of M3/M7 formations for CYP3A5 expressers was comparable to 
that for CYP3A5 non-expressers, while the S50 and Km values of M6 and M9 formations 
for CYP3A5 expressers were lower and higher than those for CYP3A5 non-expressers, 
respectively. The Vmax values of M3/M7, M6, and M9 formations for CYP3A5 
expressers were 1.73, 1.95, and 1.68-times higher than those for CYP3A5 
non-expressers, respectively. Considering CLint and CLmax values for each 
formation, M3/M7 and M6 formation activities (CLmax) in CYP3A5 expressers were 
higher than those in CYP3A5 non-expressers, but M9 formation (CLint) in CYP3A5 
expressers was comparable to that in CYP3A5 non-expressers. For DCV and BCV 
metabolism, the substrate inhibition model for M3 from DCV and the Michaelis-
Menten model for M1 from BCV were fitted as with those in rCYP3As, respectively 
(Figures 3D and 3E). The Km and Vmax values of M3 formation from DCV in 
CYP3A5 expressers were higher than and comparable to those in CYP3A5 non-
expressers, respectively. The Km and Vmax 
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values of M1 formation from BCV in CYP3A5 expressers were lower than and 
comparable to those in CYP3A5 non-expressers, respectively. From the data on CLint 
values, DCV metabolic activity in CYP3A5 expressers was comparable to that in 
CYP3A5 non-expresser, while BCV metabolism in CYP3A5 expressers was slightly 
higher than that in CYP3A5 non-expresser. 
Correlation between metabolic activities of ASV, DCV, and BCV and the 
expression level of CYP3As respectively 
The correlation between ASV, DCV, and BCV metabolites formations and the 
expression level of CYP3A proteins in 39 HLMs was determined (Table 3). Regarding 
ASV metabolism, significant correlations between the formation of all three metabolites, 
M3/M7, M6, and M9, and CYP3A4 expression level were observed. In addition, it 
should be noted that the formation of these ASV metabolites were significantly 
correlated with CYP3A5 expression level. Total of CYP3As (CYP3A4 + CYP3A5) 
expression level was also significantly correlated with the formation of ASV 
metabolites. In DCV and BCV metabolism, significant correlations between their 
metabolite formations and CYP3A4 expression level were observed. The formation of 
these metabolites was also significantly correlated with total CYP3As expression level, 
18 
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but there were no correlations between the metabolites formations and CYP3A5 
expression level.  
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Discussion 
There has been no detailed information on the contributions of CYP3A5*3 
variant on ASV, DCV, and BCV metabolism, although these drugs are known to be 
substrates for CYP3As. Here, the detailed relative contributions of CYP3A4 and 
CYP3A5 to ASV, DCV, and BCV metabolism in vitro were elucidated, and the effects 
of CYP3A5*3 variant on their metabolism were revealed using rCYP3As and HLMs. 
Several oxidative metabolite forms of ASV, DCV, and BCV were reported in previous 
studies (ref. 22, 23, 29). In addition to M3/M7 and M9, it has been reported that M12, 
which was not the area of focus in the present study, was prominently detected as ASV 
metabolite in the plasma of male healthy volunteers after ASV administration, and M6 
was not observed in their plasma (ref. 22). However, significant peaks of M3/M7, M6, 
and M9, but not M12, were detected in samples after incubation with rCYP3As as well 
as HLMs in the present study. These formations of M3/M7, M6, and M9 from ASV 
were well correlated with the remaining amount of ASV. CYP3As-medicated 
metabolism for M3/M7, M6, and M9 formations has been proposed, and M6 is known 
to be further metabolized to M9 followed by M12 formation (ref. 22). However, there is 
no direct evidence that CYP3As mediate the production of M12 from M9. Summarily, 
M3/M7, M6, and M9 could be at least considered as the main metabolites of ASV via 
20 
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CYP3As-mediated metabolism. In DCV and BCV metabolism, M3 from DCV and M1 
from BCV were reported to be the main metabolites, respectively (ref. 23, 29). Our 
results were consistent with these reports. Therefore, M3 and M1 were considered as the 
main metabolites of DCV and BCV, and these metabolites were further investigated in 
the present study. Minor contributions by the other CYPs, such as CYP1A2, 2A6, 2B6, 
2C8, 2C9, 2C19, 2D6, and 2E1, to ASV metabolism have been reported, but not at 
significant levels, and no relationship has been shown between these CYPs and the 
metabolism of DCV and BCV (ref. 22–24). In addition, selective inhibitors of these 
other CYP enzymes did not inhibit ASV metabolism to a meaningful extent, while the 
formation of ASV metabolites was strongly inhibited by the presence of ketoconazole. 
Similarly, substrate probes for CYP1A2, 2C8, 2C9, 2C19, and 2D6 did not affect the 
area under the concentration-time curve (AUC) of ASV, DCV, and BCV in healthy 
subjects (ref. 24). Our supplemental results are consistent with these findings: the 
production of all metabolites of M3/M7, M6, and M9 from ASV, as well as M3 from 
DCV and M1 from BCV, were strongly inhibited by ketoconazole (Supplementary 
figure 4). These data indicate that the main contributor to ASV, DCV, and BCV 
metabolism is CYP3As, and the contribution of other CYP enzymes is negligible.  
ASV serum concentration was correlated with liver injury represented as ALT 
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elevation after ASV administration, and high ASV exposure was observed in subjects 
with moderate and severe hepatic impairment (ref. 31–33). The discontinuation or 
reduction in ASV administration improved ALT levels in these patients, indicating that 
the level of ASV exposure is related to the incidence of AEs. However, the detailed 
mechanistic factor that could be defined as high-risk patients exhibiting AEs has been 
unknown. The present study revealed that ASV metabolic activity by CYP3A5 was 
comparable to or higher than that by CYP3A4. It is well known that the expression level 
of CYP3A5 protein in CYP3A5 expressers was significant compared to CYP3A4 (ref. 
34). Moreover, blood concentration of drugs, such as tacrolimus that has its metabolic 
activity by CYP3A5 higher than that by CYP3A4 in vitro, was high in CYP3A5 
non-expressers in clinical settings (ref. 18–20). These indicate that CYP3A5 protein in 
populations possessing at least one CYP3A5*1 allele may increase the metabolic ratio of 
ASV. Indeed, the formation of M3/M7 and M6 in CYP3A5 expressers was higher than 
that in CYP3A5 non-expressers. The significant correlation between ASV metabolism 
and CYP3A5 expression level observed in the present study may support this 
explanation. The reason for the slight difference in results between rCYP3As and HLMs 
may be because HLMs are more complex than rCYP3As. Each rCYP3A contains only 
CYP3A4 or CYP3A5, whereas HLMs contain all enzymes in the CYP family. M9 could 
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be further transformed to other metabolites. It has been reported that CYP3As have a 
significant role in both hydroxylation and loss of isoquinoline for ASV and its 
metabolites, while other CYP enzymes may play a weak role in the loss of isoquinoline 
based on experimental results obtained using inhibitors against each CYP (ref. 22). This 
could influence the production of each metabolite from another metabolite in the 
metabolic pathway. This integration of multiple factors, though weak individually, may 
have the potential to produce the observed differences between the rCYP3As and the 
HLMs. In any case, CYP3A5 and CYP3A4 are clearly of importance for the production 
of metabolites from ASV. CYP3A5*3 variant may therefore affect inter-individual 
variation in ASV exposure, and this variant may be one of the factors related to high 
exposure of ASV by decreasing ASV metabolic ratio. 
The predominance of CYP3A4-mediated metabolism in DCV has been 
reported in the drug information provided by the manufacturer as well as in several 
reports (ref. 23), and it is consistent with the results of the present study. The metabolic 
activity of DCV by CYP3A5 is far lower than that by CYP3A4. As expected, the 
importance of CYP3A5 in DCV metabolism was not observed in HLMs. The most 
significant factor in DCV metabolism is the expression of CYP3A4, and the expression 
level of CYP3A5 is not related and is not needed to be considered in DCV metabolism. 
23 
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Therefore, CYP3A5*3 may not have any clinical effect on DCV metabolism. On the 
other hand, CLmax for BCV in CYP3A5 expressers was higher than that in CYP3A5 
non-expresser, while the metabolic activity of BCV by CYP3A5 was lower than that by 
CYP3A4. However, the difference in CLmax for M1 formation between CYP3A5 
expressers and CYP3A5 non-expressers was slight, and there was no significant 
correlation between BCV metabolism and the expression level of CYP3A5. Summarily, 
the contribution of CYP3A5 expression to BCV metabolism is not completely 
negligible, and CYP3A5 might possibly be involved in BCV metabolism when 
CYP3A4 is either in low quantities or functionally impeded, but the contribution of 
CYP3A5 expression, as well as CYP3A5*3 variant to BCV metabolism might not be so 
important compared to ASV metabolism.  
CYP3As are involved in numerous drug metabolisms including ASV, DCV, and 
BCV. CYP3A4 is especially well known to have many drug-drug interactions. Famous 
CYP3A4 inhibitors such as ketoconazole and ritonavir were reported to strongly 
increase AUC of ASV, DCV, and BCV, while CYP3A4 inducers such as rifampicin were 
reported to strongly decrease AUC of ASV and DCV in several reports and drug 
information from the production company (ref. 35–37). Importantly, there was a clinical 
report that ASV/DCV administration could decrease the desired dose of tacrolimus in 
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HCV patients with liver transplantation, and ASV concentration, but not DCV 
concentration, became lower according to the reduction of tacrolimus dose (ref. 38, 39). 
This may be because the contribution of CYP3A5 might shift from tacrolimus to ASV 
according to reduction of tacrolimus dose, while CYP3A5 did not participate in DCV 
metabolism. In contrast, most of the DCV remains as the unmetabolized form in plasma 
after administration to healthy volunteers, indicating that CYP3A4 generally has low 
effects on DCV blood concentration in subjects without co-administration of any other 
drugs. However, the drug interaction with CYP3A4 should be considered when using 
drugs that are metabolized by CYP3A4 with DCV. The reports that co-administration of 
DCV with CYP3A4 inhibitors/inducers significantly changed AUC of DCV, as 
described above, along with the wide substrate specificity for CYP3A4, may support 
this explanation. Although there are no clinical reports for BCV, CYP3A5 might not 
have a strong clinical effect on BCV metabolism based on the present study. In 
summary, it is essential to consider drug-drug interaction with CYP3A4 substrates when 
using ASV, DCV, and BCV, but the interaction with drugs that have significant 
metabolic activity with CYP3A5 should be considered in only ASV. On the other hand, 
other factors such as drug transporters may involve in ASV, DCV, and BCV disposition. 
P-glycoprotein and organic anion transporters (OATP) 1B1/1B3 are reported to play a
25 
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role in the transport of ASV, DCV, and BCV (ref. 24, 40, 41). These transporters also 
interact with many other drugs, including statins, anticonvulsants, antivirals, and 
chemotherapeutics (ref. 42–44). Several substrates for these transporters are also 
important substrates for CYP3As. To fully understand the pharmacokinetics of ASV, 
DCV, and BCV, it is necessary to consider the influence of not only CYP3As, but of 
these transporters as well. Further investigation is needed to assess the utility of the 
information about these drug transporters for inter-individual variation in 
ASV/DCV/BCV therapy. In addition to laboratory-based experiments using cultured 
cells or animals overexpressing/suppressing these drug transporters and using 
inhibitors/inducers for these transporters, clinical investigation on the utility of 
combining CYP3As with these transporters is needed. 
In conclusion, this study elucidated the detailed relative contributions of 
CYP3A4 and CYP3A5 to ASV, DCV, and BCV metabolisms. CYP3A5 plays an 
important role in ASV metabolism, and CYP3A5*3 variant has a significant effect on 
ASV metabolism. However, CYP3A4 is the main enzyme for DCV and BCV 
metabolisms, and CYP3A5 plays a minor role in these metabolisms. The findings of the 
present study may provide basic information on ASV, DCV, and BCV metabolism and 
suggest that high ASV exposure may be potentially explained by CYP3A5 expression 
26 
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level. This study therefore warns against the use of drugs that are substrates for 
CYP3A5 with co-administration of ASV. In addition, CYP3A4 expression and its 
substrate levels should be considered when using ASV, DCV, and BCV. The evaluation 
of CYP3A4 and CYP3A5 expression such as by CYP3A5 genotyping before treatment 
may provide additional information on precision medicine that could be used to select 
the best treatment for HCV-infected patients. 
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Figure 1. The chemical structures of ASV, DCV, BCV, and their metabolites 
(M3/M7, M6, and M9 for ASV; M3 for DCV; M1 for BCV), and the correlation 
between the percentage of parent compound residues and the relative peak area of their 
metabolites (A, B, and C are for ASV, DCV, and BCV, respectively). Putative main 
metabolic enzymes and their reaction patterns are also represented. The chemical 
structures were provided by the pharmaceutical company Bristol-Myers Squibb (New 
York City, NY). For metabolite formations, each parent compound was incubated with 
39 HLMs for 20 min at 37 °C. The values were expressed as percentages calculated 
from 0 min of incubation and normalized by IS.  
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Figure 2. The difference in M3/M7 (A), M6 (B), M9 (C), M3 (D), and M1 (E) 
formation activities between rCYP3A4 and rCYP3A5. Open and closed circles 
represent each formation for rCYP3A4 and rCYP3A5, respectively. Various 
concentrations of each parent compound were incubated with either rCYP3A4 or 
CYP3A5 at 37 °C for 20 min. The data are represented as the peak areas for each 
metabolite normalized by IS. The substrate concentration-velocity and the 
corresponding Eadie–Hofstee plot are also shown. Each data point represents the mean 
of triplicate incubations, and error bars represent the SD. 
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Figure 3. The difference in M3/M7 (A), M6 (B), M9 (C), M3 (D), and M1 (E) 
formation activities between CYP3A5 expressers and CYP3A5 non-expressers. Closed 
and open circles represent each formation for CYP3A5 expressers and CYP3A5 
non-expressers, respectively. Various concentrations of each parent compound were 
incubated with HLMs at 37 °C for 20 min. The data are represented as the peak areas 
for each metabolite normalized by IS. The substrate concentration-velocity and the 
corresponding Eadie–Hofstee plot are also shown. Each data point represents the mean 
of triplicate incubations, and error bars represent the SD. 
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Table 1. Kinetic parameters for ASV, DCV, and BCV metabolite formations by rCYP3As (A) and CYP3A5*3-genotyped HLMs (B). 
A. Recombinant CYP3As
Metabolite 
CYP3A4 CYP3A5
Km or S50 Vmax Hill slope Type Km or S50 Vmax Hill slope Type 
ASV M3/M7 94.41 (S50)  79.30 1.259 Sigmoid 40.66 (S50) 46.45 1.259 Sigmoid 
M6 29.11 (S50)    4.81 1.260 Sigmoid      59.06 (S50)  6.80 1.385 Sigmoid 
M9 11.31 (Km)  10.21 - Michaelis 16.91 (Km)  8.42 - Michaelis
DCV M3  4. 66 (Km)   6.11 - Inhibition   5.78 (Km)  0.34 - Inhibition
BCV M1 26.83 (Km) 133.00 - Michaelis 21.05 (Km) 45.44 - Michaelis
B. HLMs
Metabolite 
Non-Expresser Expresser
Km or S50 Vmax Hill slope Type Km or S50 Vmax Hill slope Type 
ASV M3/M7 38.94 (S50) 29.44 1.392 Sigmoid 41.62 (S50) 51.03 1.203 Sigmoid 
M6 63.67 (S50)   2.37 1.680 Sigmoid       46.28 (S50)  4.62 1.244 Sigmoid 
M9 18.17 (Km)  7.33 - Michaelis 32.69 (Km) 12.28 - Michaelis
DCV M3 5. (K83 m)  0.88 - Inhibition   7.15 (Km)  0.90 - Inhibition
BCV M1 82.21 (Km) 85.50 - Michaelis 65.34 (Km) 89.92 - Michaelis
Km or S50, μM; Vmax, Relative peak area/pmol CYP/min for recombinant CYP3As or relative peak area/pmol protein/min for HLMs 
Table 2. Differences in CLint and CLmax values for ASV, DCV, and BCV metabolite 
formations between rCYP3A4 and rCYP3A5 (A) or CYP3A5 expressers and CYP3A5 
non-expressers (B). 
A. Recombinant CYP3As
Metabolite 
CLint or CLmax 
3A5/3A4 ratio 
CYP3A4 CYP3A5 
ASV M3/M7 0.505 (CLmax) 0.687 (CLmax) 1.360 
 M6 0.099 (CLmax) 0.063 (CLmax) 0.641
M9 0.903 (CLint) 0.498 (CLint) 0.551 
DCV M3 1.308 (CLint) 0.059 (CLint) 0.045
BCV M1 4.957 (CLint) 2.159 (CLint) 0.435 
B. HLMs
Metabolite 
CLint or CLmax 
Expresser/Non-expresser ratio 
Non-expresser Expresser 
ASV M3/M7 0.417 (CLmax) 0.779 (CLmax) 1.867 
 M6 0.019 (CLmax) 0.061 (CLmax) 3.207 
M9 0.403 (CLint) 0.376 (CLint) 0.932 
DCV M3 0.151 (CLint) 0.126 (CLint) 0.837 
BCV M1 1.040 (CLint) 1.376 (CLint) 1.323 
Table 3. Correlation between CYP3A expression profiles and ASV, DCV, and BCV 
metabolisms. 
Metabolite CYP3A4 CYP3A5 CYP3As (3A4 +3A5) 
ASV M3/M7 
P < 0.001 
(r = 0.525) 
P < 0.05 
(r = 0.342) 
P < 0.001 
(r = 0.621) 
M6
P < 0.001 
(r = 0.624) 
P < 0.05 
(r = 0.337) 
P < 0.001 
(r = 0.683) 
M9 
P < 0.001 
(r = 0.552) 
P < 0.05 
(r = 0.328) 
P < 0.001 
(r = 0.622) 
DCV M3 
P < 0.001 
(r = 0.667) 
P = 0.878 
(r = -0.025) 
P < 0.001 
(r = 0.525) 
BCV M1 
P < 0.001 
(r = 0.681) 
P = 0.372 
(r = 0.147) 
P < 0.001 
(r = 0.633) 
r represents Pearson’s correlation coefficient. 
